The results after a year of trial EVOLVE confirm that safety and effectiveness of the SYNERGY â„¢ Boston Scientific stent data are comparable with the of the PROMUS Element â„¢ stent of cromo platino
the results after a year of trial EVOLVE confirm that safety and effectiveness of the stent SYNERGY data ™ of Boston Scientific are comparable with the PROMUS Element stent ™ of cromo-platino presented at EuroPCR monitoring data of the study EVOLVE; in this study is being evaluated the coronary stenting of new generationliberating everolimús, of cromo-platino, with a polymer abluminal slim absorbable Natick, Massachusetts, 2012-may Boston Scientific Corporation (NYSE: BS) announces that SYNERGY ™, the eluting Coronary stent everolimus, cromo-platino, covered with a polymer absorbable, showed results of non-inferiority in the treatment of injuries of novo in the coronary arteries within one year in comparison with PROMUS Element ™Another cromo-platino in the study EVOLVE everolimus,-eluting stent that has used this system for the first time in humans. In the study there have been corresponding to one-year clinical outcomes and results of intravascular Ultrasound (IVUS) over a period of six months, to assess the safety and effectiveness of the stent SYNERGY, covered with a polymer abluminal absorbable. Dr. Stefan Verheye, interventional cardiologist of Antwerp Cardiovascular Institute, ZNA Middelheim Hospital in Belgium, today presented the results at the annual EuroPCR Congress, in Paris. The study EVOLVE had given to know the main evaluation criteria previously angiographic and clinical of non inferiority of the stent SYNERGY PROMUS Element in late 6-month loss and failure in the treated lesion (TLF) within 30 days....
Read More